ASH honors Scott Armstrong, M.D., Ph.D., with 2014 William Dameshek Prize

July 22, 2014

(WASHINGTON, July 22, 2014)--The American Society of Hematology will present the 2014 William Dameshek Prize to Scott Armstrong, MD, PhD, of Memorial Sloan Kettering Cancer Center for his exceptional work in leukemia research and cancer stem cell biology.

This prize, named after the late William Dameshek, MD, a renowned hematologist, past president of ASH, and the first editor of the Society's journal Blood, recognizes an individual who has made a recent, outstanding contribution to the field of hematology. Dr. Armstrong will accept his award at 9:30 a.m. on Tuesday, December 9, during the 56th ASH Annual Meeting and Exposition in San Francisco.

Dr. Armstrong is the Director of the Leukemia Center at Memorial Sloan Kettering Cancer Center (MSK), where he also serves as Vice Chair for Basic and Translational Research in Pediatrics and as a full member of the MSK Cancer Biology and Genetics Program. His research focuses on the biology and epigenetics of a class of leukemias initiated by mixed lineage leukemia (MLL) gene translocations. Throughout his career, Dr. Armstrong has sought to uncover unique insights into the origin and properties of cancer stem cells, the signaling pathways sustaining cancer cell self-renewal, and the epigenetic mechanisms dependent on MLL-fusion oncogenes.

In 2002 Dr. Armstrong published a seminal paper in Nature Genetics demonstrating that MLLs exhibited a unique expression signature. In subsequent papers published in Cancer Cell in 2003 and Blood in 2004, Dr. Armstrong described how the FMS-like tyrosine kinase-3 (FLT3) is highly expressed and often mutated in MLLs. Dr. Armstrong's findings, in conjunction with the work of others, have led to clinical trials of FLT3 in various forms of leukemia. Over the past several years, Dr. Armstrong has extended his elegant study of MLL-rearranged leukemic stem cells in several publications, including Nature, Science, Cancer Cell, and Blood, all while taking advantage of rapidly developing technologies in the fields of genomics, epigenetics, and stem cell biology in a quest to yield new therapies for leukemia.

Dr. Armstrong began his medical career in 1996 after earning his MD and PhD from the University of Texas Southwestern, where he trained with Nobel Laureates Joseph Goldstein, MD, and Michael Brown, MD. After completing a residency in pediatrics at Boston Children's Hospital and a clinical fellowship at Dana-Farber Cancer Institute and Boston Children's Hospital, Dr. Armstrong held a postdoctoral fellowship in the laboratory of the late Stanley Korsmeyer, MD, at Dana-Farber Cancer Institute, where he studied the molecular basis of infant leukemias instigated by MLL gene translocations. Following his postdoctoral training, Dr. Armstrong served as an attending and principal investigator in the Dana-Farber Cancer Institute pediatric hematology/oncology program, launching an independent laboratory to study the molecular genetics and therapeutics of leukemia and particularly MLL-rearranged disease, where he remained until he was recruited to MSK in 2012.

In addition to his membership to ASH, Dr. Armstrong is a member of the Society of Pediatric Research, the American Society of Pediatric Hematology/Oncology, the Society for Hematology and Stem Cells, and the American Society for Clinical Investigation. His recent awards include the American Pediatric Society and Society for Pediatric Research E. Mead Johnson Award for Research in Pediatrics, the Memorial Sloan Kettering Cancer Center Paul Marks Prize for Cancer Research, and the International Society of Experimental Hematology McCulloch and Till Award. Earlier this year, Dr. Armstrong was awarded the Frank A. Oski Memorial Award from the American Society of Pediatric Hematology/Oncology and was elected to the Association of American Physicians.

"ASH is pleased to honor Dr. Armstrong for his pioneering research in the fields of genomics and stem cell biology that is helping to fuel new therapies for patients diagnosed with devastating leukemias," said ASH President Linda J. Burns, MD, of the University of Minnesota. "His leadership and landmark discoveries in the fields of cancer stem cells and leukemia will undoubtedly leave a lasting imprint on contemporary cancer research."
The American Society of Hematology (ASH) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy. The official journal of ASH is Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online.

American Society of Hematology

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to